A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.

Trial Profile

A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Ramucirumab (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2015 Status changed from suspended to recruiting.
    • 17 Jan 2015 Protocol amendment details reported at the 2015 Gastrointestinal Cancers Symposium
    • 31 May 2014 Treatment table modified and added revised inclusion criteria as per abstract presented at 50th Annual Meeting of American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top